Healthcare Industry News: vascular access
News Release - October 18, 2011
Christie Medical Holdings Launches VeinViewer(R) FlexNew product expands existing portfolio and reach into new medical markets
MEMPHIS, Tenn.--(Healthcare Sales & Marketing Network)-- Christie Medical Holdings, Inc. today announced the market launch of the company’s newest product, VeinViewer® Flex. With the addition of this fifth-generation VeinViewer, following the recent launch of VeinViewer VisionXTND, Christie now provides a full portfolio of three product tiers that addresses the needs of every major health care market segment.
Flex, a hand-held version of VeinViewer, is designed to provide non-acute markets with the exclusive clinical capabilities of VeinViewer in a form that meets the stringent demands for durability and portability. Flex is designed to the same TrueView vein-width accuracy specifications of its predecessor, VeinViewer Vision, and is currently under testing. Additionally, Flex will feature a new software option, MaxBright, which boosts existing VeinViewer brightness by another 40 percent, making Flex one of the brightest near-infrared vein illuminators on the market. Flex is designed to be real-world durable meeting IEC/UL 60601-1 drop test standards. Christie expects to begin selling Flex later this fall.
"VeinViewer Flex greatly expands our versatility in providing a VeinViewer product solution for every customer need while extending our reach into non-acute markets, such as physician offices, blood and plasma, EMS and home health care, yet still maintaining application for NICU and ER units in the traditional hospital setting," said Chris Schnee, general manager and vice president of sales and marketing at Christie. "With the addition of Flex, Christie's VeinViewer portfolio now offers three product configurations that are uniquely capable of providing imaging solutions for the entire vascular access procedure far beyond the needle stick."
The VeinViewer technology was first introduced in 2006. VeinViewer Vision, Christie’s premier vein illumination product for hospital-wide use, comes complete with the full ASSESS imaging suite, and its mobile cart allows the fastest set-up to achieve Eyes On Patient™ hands-free technique. VeinViewer VisionXTND, with its semi-permanent mount, is optimal for single-seat procedures where the patient comes to the clinician. The Flex adds even more versatility to the product line with its mobile capabilities and application within specialty medical market segments.
The VeinViewer portfolio is capable of TrueView and digital real-time imaging via Active Vascular Imaging Navigation (AVIN). These key features positively impact the venipuncture pre-, during and post-access by helping locate valves and bifurcations, as well as a hematoma for possible avoidance of an infiltration or extravasation.
VeinViewer uses harmless near-infrared light and patented technologies to project a real-time digital image of subcutaneous vasculature and blood patterns directly onto the surface of the skin. Although designed for assistance in IV starts and blood draws, VeinViewer also is proven to be beneficial in the process of spider and varicose vein treatment.
To learn more about VeinViewer, please visit www.veinviewer.com.
About Christie Medical Holdings, Inc.
Christie Medical Holdings, Inc. is a global company based in Memphis, Tenn., that discovers, develops and commercializes medical technologies. The company’s market-leading product, VeinViewer®, is a mobile vascular imaging system that allows health care providers to clearly see accessible vasculature in real time, directly on the surface of the skin. Christie Medical Holdings, Inc. is owned by Christie Digital Systems, Inc., a global visual technologies company and a subsidiary of Ushio, Inc., Japan (JP:6925). For more information on Christie Digital Systems or Christie Medical Holdings, visit www.christiedigital.com.
Source: Christie Medical Holdings
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.